Annual revenue fell 27.5% from KRW 21.7 billion in 2022 to KRW 15.7 billion in 2023, then rose to KRW 24.6 billion in 2024 (up 56.3% year on year) and KRW 32.7 billion in 2025 (up 33.3% year on year), growing for two consecutive years. Among 2022 to 2025, 2025 was the largest year and 2023 the smallest.
Operating profit of KRW 646 million in 2022 turned into an operating loss of KRW 2.23 billion in 2023, and losses widened to an operating loss of KRW 4.93 billion in 2024. In 2025 operating profit was KRW 5.03 billion, a swing to profit, and the operating margin was 15.4%.
The operating margin moved from 3.0% in 2022 to -14.2% in 2023 and -20.1% in 2024 before reaching 15.4% in 2025. Over the same period the debt-to-equity ratio went from 114.7% to 131.6% and 93.8%, then fell to 37.5% in 2025.
Net loss attributable to controlling shareholders widened from KRW 3.77 billion in 2022 to KRW 6.28 billion in 2023 and KRW 9.33 billion in 2024, then turned to a net profit of KRW 4.64 billion in 2025. Net income including non-controlling interests moved in the same direction, at KRW 4.64 billion in 2025.
The 2025 profit reflects the licensing income the company cites. An upfront payment of about KRW 10.9 billion under the fibrosis licensing deal signed in May 2025 was recognized in 2Q, and that lifted operating profit for the quarter sharply.
Operating cash flow was KRW 5.44 billion in 2022, negative KRW 1.96 billion in 2023, KRW 291 million in 2024 and KRW 5.82 billion in 2025, so it stayed positive except in 2023.
On a quarterly basis, revenue rose from KRW 5.17 billion in 3Q 2025 to KRW 6.14 billion in 4Q 2025, but the operating loss widened from KRW 993 million to KRW 1.15 billion.
Revenue in 1Q 2026 was KRW 5.24 billion, but operating profit of KRW 137 million was a swing to profit, and the company attributed this to a roughly 35% drop in selling, general and administrative expenses.
Revenue in 2Q 2026 was KRW 6.06 billion with operating profit of KRW 103 million, while 3Q 2026 revenue of KRW 4.49 billion fell 25.9% from the prior quarter and an operating loss of KRW 783 million turned the quarter back into a loss. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 2.72 billion.